Volume 24 - Issue 3 - March 2012

Partha Sardar, MD¹, Saurav Chatterjee, MD², Debabrata Mukherjee, MD, MS³, Kirk N. Garratt, MD¹

¹Lenox Hill Cardiovascular Institute, New York, New York
²Department of Internal Medicine, Maimonides Medical Center, Brooklyn, New York
³the Department of Internal Medicine, Texas Tech Health Sciences Center, El Paso, Texas

Alessandro Lupi, MD¹, Andrea Rognoni, MD¹, Gioel Gabrio Secco, MD², Maurizio Lazzero, MD¹,
Laura Plebani, MD¹, Giuseppe Cossa, MD³, Danilo Reale, MD³, Federico Nardi, MD⁴, Mara Sansa, MD¹, Angelo S. Bongo, MD¹

Renicus S. Hermanides, MD¹, Jan Paul Ottervanger, MD, PhD¹, Jurrien M. ten Berg, MD, PhD², 
A.T. Marcel Gosselink, MD, PhD¹, Gert van Houwelingen, MD³, Jan-Henk E. Dambrink, MD, PhD¹,
Pieter R. Stella, MD, PhD⁴, Christian Hamm, MD, PhD⁵, Arnoud W.J. van ‚Äôt Hof, MD, PhD¹, on behalf of the On-TIME 2 Trial Investigators

Michael P. Thomas, MD and Hitinder S. Gurm, MD